Radioactive beads take aim at inoperable liver tumors

NCT ID NCT07110233

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This trial tests a treatment called Yttrium-90 radiation segmentectomy for people with liver cancer that can't be removed by surgery. Tiny radioactive beads are injected into the blood supply of the tumor to deliver targeted radiation. The study will enroll 64 participants to see if the treatment shrinks tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Yttrium-90 glass microspheres (TheraSphere)
What this could lead to
If successful, this could offer a new, less invasive option to control liver tumors that can't be surgically removed, potentially allowing some patients to later receive a transplant.
What could go wrong
This is an early phase 2 trial with only 64 participants, so results may not apply to everyone. There is a risk of side effects like liver damage or radiation-related issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.